There is a cure for autoimmune diabetes
What We Do
We develop therapies for the treatment of diabetes
Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development.
Two disease-modifying therapies are being developed, the antigen-specific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapy Remygen®.
Diamyd® and Remygen® target the underlying causes of diabetes, the dysfunction and loss of the insulin producing beta cells in the pancreas. Diamyd® and Remygen® are currently being evaluated in clinical trials.
Diamyd Medical’s shares are traded on Nasdaq First North, ticker DMYD B.